Final results of a phase II study of Taxotere (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)

被引：0
|
作者：
Nabholtz, JM [1 ]
Mackey, JR [1 ]
Smylie, M [1 ]
Paterson, A [1 ]
Noel, D [1 ]
Al-Twelgeri, T [1 ]
Janowska-Wieczorek, A [1 ]
Delome, F [1 ]
Riva, A [1 ]
机构：
[1] Cross Canc Inst, Dept Med, Edmonton, AB T6G 1Z2, Canada
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80164-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin and vinorelbine in metastatic breast cancer: Final results of a phase II trial
    Elsaid, A. A.
    Awad, N. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Docetaxel versus epirubicin/cyclophosphamide (EC) as first-line therapy in metastatic breast cancer (MBC): Results from the randomized phase II TIPP study.
    Wasemann, C
    Ertan, A
    Strunck, C
    Schmidt, W
    Diedrich, K
    Friedrich, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [33] Long term follow-up in untreated metastatic breast cancer (MBC) pts treated with docetaxel (Taxotere™) (T) in combination with doxorubicin (A):: Results of two studies
    Misset, JL
    Nabholtz, JM
    Dieras, V
    Noel, D
    Paterson, A
    Al Tweigeri, T
    Bozec, L
    Riva, A
    Azli, N
    Pouillart, P
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 25 - 25
  • [34] Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer.: Results from the GEPARTRIO study
    von Minckwitz, G.
    Kuemmel, S.
    du Bois, A.
    Eiermann, W.
    Eidtmann, H.
    Gerber, B.
    Hilfrich, J.
    Huober, J.
    Costa, S. D.
    Jackisch, C.
    Grasshoff, S. -T.
    Vescia, S.
    Skacel, T.
    Loibl, S.
    Mehta, K. M.
    Kaufmann, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (02) : 292 - 298
  • [35] A clinical phase II study of cisplatin and vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer (MBC).
    Yassine, H
    Khalifeh, M
    Bitar, N
    Charafeddine, M
    Dheiny, M
    Chehal, A
    Jalloul, R
    Dandashi, A
    Wehbeh, M
    Shamseddine, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 83S - 83S
  • [36] Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer
    Fasano, Julie
    Hershman, Dawn
    Novik, Yelena
    Levinson, Benjamin
    Blozie, Kim
    Tiersten, Amy D.
    [J]. BREAST CARE, 2010, 5 (01) : 17 - 21
  • [37] A phase I study of dose-dense docetaxel (D) with cyclophosphamide (C) as first line in patients (pts) with metastatic breast cancer (MBC).
    Hocini, H
    Cottu, P
    Cuvier, C
    Romieux, G
    Culine, S
    Lerebours, F
    Espie, M
    Boccara, C
    Marty, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 24 - 24
  • [38] Primary chemotherapy with gemcitabine, doxorubicin and docetaxel for early breast cancer: Final results of a Phase-II trial
    Mross, Klaus
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (07) : 423 - 424
  • [39] Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer
    Goel, Shom
    Abdi, Ehtesham
    Lewis, Craig R.
    Links, Matthew
    Begbie, Steven
    Clingan, Philip
    Ganju, Vinod
    Beith, Jane
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (01) : 32 - 38
  • [40] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
12345